Search Result

Results for "

α2C

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (13) Adrenergic Receptor (34) Androgen Receptor (1) Apoptosis (1) Dopamine Receptor (10) G protein-coupled Bile Acid Receptor 1 (1) Histamine Receptor (4) Isotope-Labeled Compounds (3) mAChR (2) Opioid Receptor (1) PTHR (1) Reference Standards (3) Sigma Receptor (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (6) Endocrinology (8) Inflammation/Immunology (1) Metabolic Disease (3) Neurological Disease (29)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15780

Brexpiprazole Maximum Cited Publications 6 Publications Verification OPC-34712	5-HT Receptor Dopamine Receptor Adrenergic Receptor	Neurological Disease
Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and *dopamine D_2L* receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a K_i** of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α_1B (K_i=0.17 nM) and α_2C receptors (K_i=0.59 nM) ^[2].

HY-103213

JP1302 dihydrochloride 2 Publications Verification	Adrenergic Receptor	Neurological Disease Endocrinology
JP1302 dihydrochloride is a potent, selective, high affinity antagonist of the *α_2C-adrenoceptor, with a K_b* of 16 nM and a K_i of 28 nM for the human α_2C-receptor. JP1302 dihydrochloride shows antidepressant and antipsychotic-like effects. JP1302 dihydrochloride can be used for neuropsychiatric disorders and renal dysfunction research ^[2] .

HY-101198

Clobenpropit dihydrobromide	Histamine Receptor Apoptosis	Neurological Disease Cancer
Clobenpropit dihydrobromide is a potent histamine H3R antagonist/inverse agonist with a pEC₅₀ of 8.07 for histamine H3LR . Clobenpropit dihydrobromide acts as partial agonist at histamine H4 receptors (K_i 13 nM). Clobenpropit dihydrobromide also binds to serotonin 5-HT3 receptors (K_i 7.4 nM) and α2A/α2C adrenoceptors (K_i 17.4/7.8 nM) ^[2]. Clobenpropit dihydrobromide increases apoptosis .

HY-159639

BAY-2925976	Androgen Receptor	Neurological Disease
BAY-2925976 is an α2C adrenergic receptor (ARα2C) antagonist that can be used for the study of obstructive sleep apnea (OSA) .

HY-15780S1

Brexpiprazole-d8-1 OPC-34712-d₈-1	Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease
Brexpiprazole-d₈-1 (OPC-34712-d₈-1) is the deuterium labeled Brexpiprazole (HY-15780) . Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and *dopamine D_2L* receptor with K_i*s of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A* receptor antagonist with a K_i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (K_i=0.17 nM) and α2C receptors (K_i=0.59 nM) ^[2] .

HY-103213A

JP1302 2 Publications Verification	Adrenergic Receptor	Neurological Disease
JP1302 is a potent, selective, high affinity antagonist of the *α_2C-adrenoceptor, with a K_b* of 16 nM and a K_i of 28 nM for the human α_2C-receptor. JP1302 shows antidepressant and antipsychotic-like effects. JP1302 can be used for neuropsychiatric disorders and renal dysfunction research ^[2] .

HY-101610

OPC-28326	Adrenergic Receptor	Cardiovascular Disease Endocrinology
OPC-28326 is a selective peripheral vasodilator and an angatonist of α2-adrenergic receptor, with K_i of 2040, 285, and 55 nM for α2A-, α2B- and α2C-adrenoceptors, respectively.

HY-103212A

Azepexole hydrochloride B-HT 933 hydrochloride; Oxazoloazepin hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Azepexole hydrochloride (B-HT 933 dihydrochloride; Oxazoloazepin dihydrochloride) is a selective agonist for α 2-adrenoceptor, with pK_i of 8.3, 7.6, and 7.5 for α2A-, α2B- and α2C-adrenoceptor subtypes, resepctively. Azepexole dihydrochloride causes concentration-dependent inhibition of peristaltic contractions with IC₅₀ of 78.72 nM. Azepexole hydrochloride exhibits antitussive and analgesic efficacy ^[2].

HY-B0371D

(S)-Terazosin	Adrenergic Receptor	Endocrinology
(S)-Terazosin is an active S-enantiomer of Terazosin. (S)-Terazosin is a potent and high-affinity α-adrenoceptor antagonist with K_i values of 3.91 nM, 0.79 nM and 1.16 nM for α1a, α1b and α1d-adrenoceptor, respectively. (S)-Terazosin also has high-affinity for *α2a, α2B* and *α2c*-adrenoceptor with K_i values of 729 nM, 3.5 nM and 46.4 nM, respectively .

HY-15780R

Brexpiprazole (Standard) OPC-34712 (Standard)	Reference Standards 5-HT Receptor Dopamine Receptor Adrenergic Receptor	Neurological Disease
Brexpiprazole (Standard) is the analytical standard of Brexpiprazole. This product is intended for research and analytical applications. Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and *dopamine D_2L* receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a K_i** of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α_1B (K_i=0.17 nM) and α_2C receptors (K_i=0.59 nM) ^[2].

HY-15780S

Brexpiprazole-d8 OPC-34712-d₈	Isotope-Labeled Compounds 5-HT Receptor Dopamine Receptor Adrenergic Receptor	Neurological Disease
Brexpiprazole-d₈ (OPC-34712-d₈) is the deuterium labeled Brexpiprazole (HY-15780). Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and *dopamine D_2L* receptor with K_i*s of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A* receptor antagonist with a K_i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (K_i=0.17 nM) and α2C receptors (K_i=0.59 nM) ^{^[2] .}

HY-158194

α2C adrenoceptor agonist 1	Adrenergic Receptor	Cancer
α2C adrenoceptor agonist 1 (Compound A) is an orally active, highly selective, and non-central nervous system penetrating agonist for the *α2C-adrenoceptor, with EC₅₀* and K_i values of 108 nM and 12 nM, respectively. α2C adrenoceptor agonist 1 can be used in the study of nasal congestion .

HY-114814

ORM-10921 free base	Adrenergic Receptor	Neurological Disease
ORM-10921 free base is a selective α-2C adrenergic receptor antagonist with a K_i of 1.4 nM. ORM-10921 free base displays potent antidepressant and antipsychotic-like effects .

HY-101338A

RS-79948-197 hemihydrate RS-79948 hydrochloride hemihydrate	Adrenergic Receptor	Neurological Disease
RS-79948-197 hemihydrate is a non-imidazoline *α2-adrenoceptor* antagonist. RS-79948-197 hemihydrate shows K_d values of 0.42 nM, 0.18 nM, 0.19 nM, 0.60 nM, 0.46 nM, and 0.77 nM for rat α2A, rat α2B, rat α2C, human α2A, human α2B, and human α2C, respectively ^[2].

HY-101338

RS-79948-197 RS-79948 hydrochloride	Adrenergic Receptor	Neurological Disease
RS-79948-197 is a non-imidazoline *α2-adrenoceptor* antagonist. RS-79948-197 shows K_d values of 0.42 nM, 0.18 nM, 0.19 nM, 0.60 nM, 0.46 nM, and 0.77 nM for rat α2A, rat α2B, rat α2C, human α2A, human α2B, and human α2C, respectively ^[2].

HY-W741575

Iloperidone carboxylic acid P95-12113	5-HT Receptor Adrenergic Receptor Dopamine Receptor	Neurological Disease
Iloperidone carboxylic acid (P95-12113) is the metabolite of Iloperidone (HY-17410). Iloperidone carboxylic acid exhibits good affinity for 5-HT2A receptor with pK_i of 8.15, and moderate affinity for adrenergic receptor α1/α2B/α2C .

HY-15780A

Brexpiprazole hydrochloride OPC-34712 hydrochloride	5-HT Receptor Dopamine Receptor Adrenergic Receptor	Neurological Disease
Brexpiprazole (OPC-34712) hydrochloride, an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and *dopamine D_2L* receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole hydrochloride is also a 5-HT2A receptor antagonist with a K_i** of 0.47 nM. Brexpiprazole hydrochloride also shows potent antagonist activity at human noradrenergic α_1B (K_i=0.17 nM) and α_2C receptors (K_i=0.59 nM) ^[2].

HY-U00117

Lusaperidone R107474	Adrenergic Receptor	Neurological Disease Endocrinology
Lusaperidone (R107474) is an α2 adrenergic receptor antagonist with K_is of 0.13 and 0.15 nM for α2A and α2C, respectively.

HY-109130

Fadaltran BAY 1193397	Adrenergic Receptor	Metabolic Disease
Fadaltran (BAY 1193397) is an orally active *α2C-adrenoreceptor* antagonist. Fadaltran can be used for the study of diabetic foot ulcers .

HY-B0032S

Lurasidone-d8 hydrochloride SM-13496-d8 hydrochloride	Isotope-Labeled Compounds Dopamine Receptor 5-HT Receptor	Neurological Disease
Lurasidone-d₈ (hydrochloride) is the deuterium labeled Lurasidone, which is an inhibitor of Dopamine D2, 5-HT2A, 5-HT7, 5-HT1A and noradrenaline α2C.

HY-12709

ARC 239 1 Publications Verification	Adrenergic Receptor 5-HT Receptor	Neurological Disease
ARC 239 is an α2B/C-adrenergic receptor antagonist with pK_i of 7.06 and 6.95 for rat kidney α2B and human α2C, respectively. ARC 239 also inhibits 5-HT1A receptor with a K_i of 63.1 nM ^[2].

HY-113918

SW-106	PTHR	Metabolic Disease
SW-106 is a selective antagonist of parathyroid hormone/parathyroid hormone-related peptide receptor (PPR) and PTHR1, with an IC₅₀ value of 0.99 μM against PPR. SW-106 antagonizes cAMP responses. SW-106 can be used in the research of osteoporosis ^[2].

HY-12709A

ARC 239 dihydrochloride 1 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology
ARC 239 dihydrochloride is a selective α2B/2C adrenoceptor antagonist (pK_d values are 5.95, 7.41 and 7.56 at α2A, α2B, and α2C receptors respectively). ARC 239 dihydrochloride binds to CHO cell membranes expressing human recombinant a2A-, a2B- or a2C-adrenoceptor subtypes with pK_is of 5.6, 8.4, and 7.08, respectively .

HY-U00244

Benzquinamide P2647; BZQ; Benzoquinamide	Adrenergic Receptor Dopamine Receptor	Metabolic Disease
Benzquinamide (P2647; BZQ; Benzoquinamide) is an orally active binder of dopamine receptors and adrenergic receptors. Benzquinamide specifically targets dopamine D2, D3, D4 receptors and **α-2A, α-2B, α-2C** adrenergic receptors. Benzquinamide regulates blood pressure and heart rate, attenuates the pressor effect of adrenaline, and exhibits activities such as antiemesis, anxiolysis, and reduction of histamine-induced bronchoconstriction. Benzquinamide has good safety and does not deplete serotonin or norepinephrine in the brain. Benzquinamide can be used in studies related to nausea/vomiting, mental disorders, anxiety states, neurosis, and psychosis ^[2].

HY-172339

4-AcO-DALT hydrochloride 4-Acetoxy DALT hydrochloride	5-HT Receptor Adrenergic Receptor Dopamine Receptor Histamine Receptor mAChR Sigma Receptor	Neurological Disease
4-AcO-DALT hydrochloride is a tryptamine compound with psychoactive effects. 4-AcO-DALT hydrochloride inhibits 5-HT receptors, alpha receptors, dopamine receptors, histamine receptor 1 (H1), muscarinic M2 receptor and Sigma 2 receptor. 4-AcO-DALT hydrochloride shows K_i values of 582 nM, 2689 nM, 2099 nM, 2116 nM, 958 nM, 137 nM, 824 nM, 479 nM, 406 nM, 874 nM, 4190 nM, 482 nM, 214 nM, 803 nM, 4522 nM, 1907 nM for 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, 5-HT7A, H1, Sigma 2, α2A, α2B, α2C, D2, D3 receptors ^[2].

HY-117046

AVN-101	5-HT Receptor Histamine Receptor Adrenergic Receptor	Neurological Disease
AVN-101 is a potent, brain-penetrant and orally active 5-HT7 receptor antagonist (K_i of 153 pM), with slightly lesser potency toward 5-HT6, *5-HT2A, and 5HT-2C* receptors (K_i values of 2.04 nM, 1.56 nM, and 1.17 nM, respectively). AVN-101 also exhibits a rather high affinity toward histamine H1 (K_i of 0.58 nM) and adrenergic α2A, *α2B, and α2C* (K_i= 0.41-3.6 nM) receptors. AVN-101 can be studied in such diseases as general anxiety disorders, depression, schizophrenia, Alzheimer’s disease, and multiple sclerosis .

HY-103213R

JP1302 dihydrochloride (Standard)	Reference Standards Adrenergic Receptor	Neurological Disease Endocrinology
JP1302 dihydrochloride (Standard) is the analytical standard of JP1302 dihydrochloride. This product is intended for research and analytical applications. JP1302 dihydrochloride is a potent, selective, high affinity antagonist of the α2C-adrenoceptor, with a Kb of 16 nM and a Ki of 28 nM for the human α2C-receptor. JP1302 dihydrochloride shows antidepressant and antipsychotic-like effects. JP1302 dihydrochloride can be used for neuropsychiatric disorders and renal dysfunction research ^[2] .

HY-100300

AGN 192836	Adrenergic Receptor	Cardiovascular Disease Endocrinology
AGN 192836 is a potent and selective α2 adrenergic agonist with EC₅₀s of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively.

HY-138839

Allyphenyline oxalate	Opioid Receptor	Neurological Disease
Allyphenyline oxalate (compound 9) can enhance the analgesic effect of Morphine. The pKi values of Allyphenyline for α2A, α2B and α2C are 7.24, 6.47 and 7.07, respectively .

HY-106400

EGIS 11150	Adrenergic Receptor	Neurological Disease
EGIS 11150 is a adrenergic reporter antagonist that has high affinity for adrenergic α₁, α_2c, 5-HT_2A reporters. EGIS 11150 is an antipsychotic compound with procognitive efficacy .

HY-W042920A

TDIQ hydrochloride	Adrenergic Receptor	Neurological Disease
TDIQ hydrochloride is an analog of Amphetamine with high affinity for α2-adrenergic receptor. TDIQ hydrochloride is a selective α2-adrenoceptor ligand with the K_i values of 75 nM, 95 nM, and 65 nM for α2A-, α2B-, and α2C-adrenergic receptors, respectively .

HY-106444

Fipamezole MPV 1730; JP-1730	Adrenergic Receptor	Neurological Disease
Fipamezole (MPV 1730; JP-1730) is a potent and orally active α2-adrenergic receptor antagonist with K_i values of 9.2 nM, 17 nM, and 55 nM for human α2A, α2B, and α2C, receptors, respectively. Fipamezole is an anti-dyskinetic agent, and can be used for the study of Parkinson's disease .

HY-103212

Azepexole dihydrochloride B-HT 933 dihydrochloride; Oxazoloazepin dihydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Azepexole (B-HT 933) dihydrochloride is a potent and selective alpha 2-adrenoceptor agonist with pK_is of 8.3, 7.6, and 7.5 for α2A-, α2B- and α2C-adrenoceptor subtypes, resepctively . Azepexole dihydrochloride causes concentration-dependent inhibition of peristaltic contractions (IC₅₀= 78.72 nM) ^[2].

HY-12709R

ARC 239 (Standard)	Adrenergic Receptor 5-HT Receptor	Neurological Disease
ARC 239 (Standard) is the analytical standard of ARC 239. This product is intended for research and analytical applications. ARC 239 is an α2B/C-adrenergic receptor antagonist with pKi of 7.06 and 6.95 for rat kidney α2B and human α2C, respectively. ARC 239 also inhibits 5-HT1A receptor with a Ki of 63.1 nM ^[2].

HY-U00244A

Benzquinamide hydrochloride P2647 hydrochloride; BZQ hydrochloride; Benzoquinamide hydrochloride	Adrenergic Receptor Dopamine Receptor	Neurological Disease
Benzquinamide (P2647; BZQ; Benzoquinamide) hydrochloride is an orally active binder of dopamine receptors and adrenergic receptors. Benzquinamide hydrochloride specifically targets dopamine D2, D3, D4 receptors and **α-2A, α-2B, α-2C** adrenergic receptors. Benzquinamide hydrochloride regulates blood pressure and heart rate, attenuates the pressor effect of adrenaline, and exhibits activities such as antiemesis, anxiolysis, and reduction of histamine-induced bronchoconstriction. Benzquinamide hydrochloride has good safety and does not deplete serotonin or norepinephrine in the brain. Benzquinamide hydrochloride can be used in studies related to nausea/vomiting, mental disorders, anxiety states, neurosis, and psychosis ^[2].

HY-P5846

Muscarinic toxin 3 MT3	mAChR Adrenergic Receptor	Neurological Disease
Muscarinic toxin 3 (MT3) is a potent and non-competitive mAChR and adrenoceptors antagonist with pIC₅₀s of 6.71, 8.79, 8.86, 7.57, 8.13, 8.49, <6.5, 7.29 against M₁, M₄, α_1A, α_1B, α_1D,α_2A,α_2B and α_2C receptors, respectively. Muscarinic toxin 3 displays prominent adrenoceptor activity .

HY-117046A

AVN-101 hydrochloride	5-HT Receptor Histamine Receptor Adrenergic Receptor	Neurological Disease
AVN-101 hydrochloride is a potent, brain-penetrant and orally active 5-HT7 receptor antagonist (K_i of 153 pM), with slightly lesser potency toward 5-HT6, *5-HT2A, and 5HT-2C* receptors (K_i values of 2.04 nM, 1.56 nM, and 1.17 nM, respectively). AVN-101 hydrochloride also exhibits a rather high affinity toward histamine H1 (K_i of 0.58 nM) and adrenergic α2A, *α2B, and α2C* (K_i= 0.41-3.6 nM) receptors. AVN-101 hydrochloride can be studied in such diseases as general anxiety disorders, depression, schizophrenia, Alzheimer’s disease, and multiple sclerosis .

HY-106444A

Fipamezole hydrochloride MPV-1730 hydrochloride; JP-1730 hydrochloride	Adrenergic Receptor	Neurological Disease
Fipamezole hydrochloride is a potent and orally active α2-adrenergic receptor antagonist with K_i values of 9.2 nM, 17 nM, and 55 nM for human α2A, α2B, and α2C, receptors, respectively. Fipamezole hydrochloride is an anti-dyskinetic agent, and can be used for the study of Parkinson's disease .

HY-100300R

AGN 192836 (Standard)	Adrenergic Receptor Reference Standards	Cardiovascular Disease Endocrinology
AGN 192836 (Standard) is the analytical standard of AGN 192836 (HY-100300). This product is intended for research and analytical applications. AGN 192836 is a potent and selective α2 adrenergic agonist with EC50s of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively.

HY-121675A

2-Bromo-LSD D-Tartrate BOL-148 D-Tartrate; Bromolysergide D-Tartrate	5-HT Receptor G protein-coupled Bile Acid Receptor 1	Neurological Disease
2-Bromo-LSD D-Tartrate (BOL-148 D-Tartrate) is a blood-brain barrier-permeable *5-HT_2A* partial agonist and competitive partial antagonist. 2-Bromo-LSD D-Tartrate acts as both a potent partial agonist (with an EC₅₀ of 0.81 nM for Gq dissociation) and a potent partial antagonist (with a K_B of 0.18 nM for Gq dissociation) at the 5-HT_2A receptor. 2-Bromo-LSD D-Tartrate exhibits partial agonist activity at multiple aminergic GPCRs, including 5-HT_2A. 2-Bromo-LSD D-Tartrate lacks *5-HT_2B* agonist activity. 2-Bromo-LSD D-Tartrate induces dendritogenesis and spinogenesis. 2-Bromo-LSD D-Tartrate reverses the behavioral effects of chronic stress and increases active coping behaviors in mice ^[2].

Cat. No.	Product Name	Target	Research Area

HY-P5846

Muscarinic toxin 3 MT3	mAChR Adrenergic Receptor	Neurological Disease
Muscarinic toxin 3 (MT3) is a potent and non-competitive mAChR and adrenoceptors antagonist with pIC₅₀s of 6.71, 8.79, 8.86, 7.57, 8.13, 8.49, <6.5, 7.29 against M₁, M₄, α_1A, α_1B, α_1D,α_2A,α_2B and α_2C receptors, respectively. Muscarinic toxin 3 displays prominent adrenoceptor activity .

Cat. No.	Product Name	Chemical Structure

HY-15780S1

Brexpiprazole-d8-1
Brexpiprazole-d₈-1 (OPC-34712-d₈-1) is the deuterium labeled Brexpiprazole (HY-15780) . Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and *dopamine D_2L* receptor with K_i*s of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A* receptor antagonist with a K_i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (K_i=0.17 nM) and α2C receptors (K_i=0.59 nM) ^[2] .

Brexpiprazole-d8-1

Brexpiprazole-d₈-1 (OPC-34712-d₈-1) is the deuterium labeled Brexpiprazole (HY-15780) . Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D_2L receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a K_i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (K_i=0.17 nM) and α2C receptors (K_i=0.59 nM) ^[2] .

HY-15780S

Brexpiprazole-d8
Brexpiprazole-d₈ (OPC-34712-d₈) is the deuterium labeled Brexpiprazole (HY-15780). Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and *dopamine D_2L* receptor with K_i*s of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A* receptor antagonist with a K_i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (K_i=0.17 nM) and α2C receptors (K_i=0.59 nM) ^{^[2] .}

Brexpiprazole-d8

Brexpiprazole-d₈ (OPC-34712-d₈) is the deuterium labeled Brexpiprazole (HY-15780). Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D_2L receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a K_i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (K_i=0.17 nM) and α2C receptors (K_i=0.59 nM) ^{^[2] .}

HY-B0032S

Lurasidone-d8 hydrochloride
Lurasidone-d₈ (hydrochloride) is the deuterium labeled Lurasidone, which is an inhibitor of Dopamine D2, 5-HT2A, 5-HT7, 5-HT1A and noradrenaline α2C.

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81048

	Collagen VI A1+A2+A3 Antibody (YA893) Alpha 1 (VI) chain (61 AA) antibody; CO6A1_HUMAN antibody; COL6A1 antibody; Collagen alpha-1(VI) chain antibody; Collagen type VI alpha 1 antibody; Collagen VI alpha 1 polypeptide antibody; Collagen VI antibody; Human mRNA for collagen VI alpha 2 C terminal globular domain antibody; OPLL antibody; PP3610 antibody	WB, ICC/IF, IHC-P	Human, Mouse, Rat
	Collagen VI A1+A2+A3 Antibody (YA893) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Collagen VI A1+A2+A3.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: